Riskpilot← Back to searchSign inGet full accessSCANPHARM A/S
A/SActiveCVR 16279099Topstykket 12Manufacture of pharmaceutical preparations · NACE 2120Est. 199243 employees
Revenue 2024
DKK 26,9M
+19% vs 2023
EBITDA margin
10.9%
+262% vs 2023
Equity ratio
5.9%
Financial strength
Net profit 2024
DKK 583K
+113% vs 2023
| Revenue | DKK 26,9M | +19% |
| EBITDA | DKK 2,9M | +262% |
| Net profit | DKK 583K | +113% |
| Total assets | DKK 35,1M | +11% |
| Equity | DKK 2,1M | +39% |
| Employees | 43 | — |
Legal name
SCANPHARM A/S
CVR number
16279099
Legal form
Aktieselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
1. juli 1992
Share capital
DKK 3.000.000
Employees
43 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsens formand og en direktør i forening eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at drive handel og produktion
Address
Topstykket 12
Phone
+4545826046
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.949 | 20.770 | 20.447 | 19.627 | 19.072 | 19.564 | 17.830 | 5.118 | 11.259 | 17.399 | 22.519 | 26.904 |
| Staff expenses | -18.027 | -17.413 | -17.074 | -16.138 | -17.684 | -19.957 | -19.495 | -19.391 | -18.906 | -21.128 | -24.335 | -23.962 |
| EBITDA | 1.330 | 1.848 | 2.147 | 3.488 | 1.388 | -393 | -1.666 | -14.273 | -7.981 | -3.394 | -1.815 | 2.942 |
| Depreciation & amort. | -0 | -0 | -0 | -1.278 | -1.358 | -2.430 | -1.564 | -1.823 | -1.737 | -1.811 | -1.717 | -1.263 |
| EBIT | 1.330 | 1.848 | 2.147 | 2.210 | 30 | -2.823 | -3.230 | -16.096 | -9.718 | -5.205 | -3.533 | 1.679 |
| Net financials | -725 | -935 | -1.320 | -739 | -752 | -918 | -778 | -1.003 | -1.066 | -1.408 | -986 | -1.135 |
| Profit before tax | 605 | 913 | 828 | 1.625 | -283 | -3.680 | -3.978 | -17.099 | -10.785 | -6.106 | -4.425 | 583 |
| Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 1.842 | 86 | -151 | -0 | -0 |
| Net profit | 400 | 431 | 716 | 1.267 | -228 | -2.876 | -3.978 | -18.941 | -10.871 | -5.954 | -4.425 | 583 |
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 34.490 | 33.667 | 31.126 | 33.402 | 41.492 | 38.186 | 35.162 | 32.224 | 28.911 | 29.659 | 31.602 | 35.068 |
| Equity | 10.558 | 10.989 | 11.705 | 12.972 | 12.743 | 9.867 | 5.889 | 1.913 | 1.500 | 1.500 | 1.500 | 2.083 |
| Long-term debt | 0 | 0 | 0 | 0 | 3.354 | 2.727 | 4.497 | 5.181 | 3.946 | 2.907 | 3.625 | 3.138 |
| Short-term debt | 23.932 | 22.678 | 19.422 | 20.430 | 24.668 | 25.593 | 24.776 | 25.131 | 23.465 | 25.252 | 26.476 | 29.847 |
| Total debt | 23.932 | 22.678 | 19.422 | 20.430 | 28.022 | 28.319 | 29.273 | 30.311 | 27.411 | 28.159 | 30.102 | 32.986 |
EBITDA margin
10.9%
This company
15.8%
Market median
-31% vs market
20132024
Equity ratio
5.9%
This company
38.2%
Market median
-85% vs market
20132024
Return on equity
28.0%
This company
18.4%
Market median
+52% vs market
20132024
Net profit margin
2.2%
This company
8.1%
Market median
-73% vs market
20132024
Asset turnover
0.77×
This company
1.12×
Market median
-31% vs market
20132024
Debt / equity
15.84×
This company
0.62×
Market median
-2455% vs market
20132024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
RE Management | Management | 2018 | — | — |
BL Audit | Audit | 2007 | — | — |
ET | Audit | 1992 | — | — |
OB Management | Management | 1992 | — | — |
AB Chief Executive Officer | Chief Executive Officer | 2019 | — | — |
PE Management | Management | 1992 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 1992 | — | — | |
| Chairman | 2010 | — | — | |
| Chairman | 1992 | — | — | |
| Board of Directors | 1992 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 1999 | — | — | |
| Board of Directors | 1992 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
CHLOPETHAN A/S | Company | 90.0% | 90.0% | 2019 |
Peluli Holding ApS | Company | 10.0% | 10.0% | 2018 |
E CONSULT ApS | Company | 10.0% | 10.0% | 2018 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Peluli Holding ApS
SCANPHARM A/S Board members of SCANPHARM A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Rolf Eckersberg | Management | 0 companies |
| Bent Lind Kofoed | Audit | 0 companies |
| Erik Tronborg Andersen | Audit | 0 companies |
| Ole Bjørn Jensen | Management | 0 companies |
| Andreas Bjørn Jensen | Chief Executive Officer | 0 companies |
| Per Emil Hasselbalch Stakemann | Management | 0 companies |
| Hanne Bjørn Jensen | Board of Directors | 0 companies |
| Holger Carsten Hansen | Chairman | 0 companies |
| Ulf Svejgaard Poulsen | Chairman | 0 companies |
| Kim Aage Egegaard | Board of Directors | 0 companies |
| Janus Doré Pagh | Chairman | 0 companies |
| Jens Terkel Lund-Nielsen | Board of Directors | 0 companies |
| Hans Christian Galst | Board of Directors | 0 companies |